"AstraZeneca's Tagrisso Revolutionizes Lung Cancer Treatment with FDA Approval and Promising Trial Results"
TL;DR Summary
AstraZeneca has reported positive results in the treatment of lung cancer, with its drug Tagrisso showing significant improvement in overall survival rates compared to standard chemotherapy. The pharmaceutical company's study demonstrated a 21% reduction in the risk of death for patients receiving Tagrisso, marking a significant advancement in the field of lung cancer treatment.
- AstraZeneca unveils successes in treatment of lung cancer Financial Times
- U.S. FDA approves AstraZeneca's Tagrisso-chemo combo Reuters
- AstraZeneca Shares Top FTSE 100 Index Risers After Tagrisso Gets U.S. Approval MarketWatch
- AstraZeneca Expands Tagrisso’s NSCLC Label, FDA Allows Use with Chemo BioSpace
- AstraZeneca's Tagrisso shows improved results in LAURA phase -III trial (NASDAQ:AZN) Seeking Alpha
Reading Insights
Total Reads
0
Unique Readers
28
Time Saved
1 min
vs 1 min read
Condensed
67%
166 → 54 words
Want the full story? Read the original article
Read on Financial Times